Blog
Welcoming FITCI’s Newest Soft Landing Company: Univision Global Sourcing
Welcome to FITCI, Univison Global Sourcing! For those who may not be familiar, FITCI partners with Maryland’s Global Gateway Soft Landing Program to help international companies explore the U.S. market and build connections right here in Maryland. The program gives companies an opportunity to test the waters, establish a presence, and learn what it takes … Read more
Countdown to Tech Showcase 2026 ▶︎ Company Spotlight: CFrame
With the 2026 Tech Showcase fast approaching we are spotlighting FITCI companies leading up to it. Follow along to learn more about the companies featured in this years Tech Showcase, and the groundbreaking technology, research, and science happening in right here in Frederick. Discredited human experience, disconnection, and unrealized potential are just some of the … Read more
BioEvanesce: Pioneering Solutions for Post-Surgical Scar Tissue Adhesions
In June 2024, BioEvanesce established its laboratory at FITCI, Frederick’s leading incubator for life sciences and technology startups. The company is on a mission to tackle a pervasive and often overlooked post-surgical complication that affects millions of patients each year: Scar Tissue Adhesions. “Adhesions are the bane of surgeons’ existence,” says BioEvanesce founder, Erin Evke, a PhD … Read more
Theradaptive Grows Again; Celebrates Ribbon-Cutting
September 19, 2024 – Founded in 2016, FITCI Grad Theradaptive is growing again. The company is commercializing a pipeline of therapeutics in the orthopedic space, targeting multiple clinical applications, including spinal fusion, long bone repair, dental repair, osteochondral reconstruction, and peripheral nerve repair. It launched from FITCI’s Metropolitan Court facility with 6 employees during the … Read more
Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Source: Veralox Frederick, MD, Aug. 14, 2024 – Veralox Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced that the European Medicines Agency (EMA) has granted Orphan … Read more
